GSK (GSK) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for GSK (NYSE: GSK):

• 12/22/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – GSK had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc.
• 12/8/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – GSK was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating.
• 11/20/2025 – GSK had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 10/31/2025 – GSK was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 10/30/2025 – GSK was given a new $53.00 price target on by analysts at Cfra.
• 10/27/2025 – GSK had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Friday, November 14th will be paid a $0.4171 dividend. This represents a $1.67 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s payout ratio is presently 46.33%.

Insider Activity

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the transaction, the insider directly owned 18,245,691 shares in the company, valued at $346,668,129. This trade represents a 8.76% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is owned by company insiders.

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.